Brief: Xilio Therapeutics Announces Initial Clinical Trial Data From Phase 1C Dose Escalation For Vilastobart
07/11/2024 14:29
Nov 7 (Reuters) - Xilio Therapeutics Inc XLO.O :
* XILIO THERAPEUTICS ANNOUNCES INITIAL CLINICAL TRIAL DATA
FROM
PHASE 1C DOSE ESCALATION FOR VILASTOBART (XTX101), A
TUMOR-ACTIVATED ANTI-CTLA-4, IN COMBINATION WITH ATEZOLIZUMAB IN
PATIENTS WITH ADVANCED SOLID TUMORS
* XILIO THERAPEUTICS INC - VILASTOBART AND ATEZOLIZUMAB
GENERALLY
WELL-TOLERATED
* XILIO THERAPEUTICS INC - INITIAL PHASE 2 DATA EXPECTED IN
Q4
2024
Source text: ID:nGNX7ppWlf
Further company coverage: XLO.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Xilio Therapeutics
See all newsXilio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Xilio Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates
U.S. STOCKS ON THE MOVE-Palantir, AeroVironment, Valvoline
U.S. STOCKS ON THE MOVE-Medtronic, AeroVironment, Tesla